Table A1.

HPV-FRAME reporting standards for models of vaccination in adolescent individuals.

a) Inputs	Reported? (Y/N)	Reported by age? (Y/N)	Report by sex?	Comments
Vaccine uptake	Y	Y	Y	Uptake by number of doses, age, sex
Vaccine efficacy	Y	Y	Y	Efficacy by number of doses, age, sex, HPV type
Vaccine cross-protection	Y	N/A	N/A	Level and duration of protection by dose and type.
Duration vaccine protection and waning	Y	Y	Y (report by sex and site/disease if applicable)	Duration of vaccine protection and waning assumptions. Report base case assumption and sensitivity analysis on duration of protection
Vaccine and delivery costs	Y	Y (if applicable)	Y (if applicable)	Vaccine-related cost assumptions (by sex if they differ) including infrastructure (overhead), administration, cost per dose. Delivery mechanism
Pre-vaccination disease burden (including population attributable fractions for HPV)	Y	Y	Y (if applicable)	Pre-vaccination disease burden included when assessing effect on infections and cancer or pre-vaccination cancer burden for population attributable fractions.
Duration of natural immunity	Y	Y	Y	Comment on waning function
b) Outputs	Reported? (Y/N)	Report by age? (Y/N)	Report by sex? (B, F, or M)	Report as calibration or validation target? (Y/N)
Absolute reductions in HPV infections, and/or warts, post-vaccination	Y	Y	As appropriate to evaluation	Y
Absolute reductions in CIN2+ post-vaccination	Y	Y	As appropriate to evaluation	Y. Suggested comparison to vaccine trial data; consideration should be given to trial-based modelling to support this validation process, and/or comment should be made on the applicability and external validity of the trial data to the situation being modelled.
Absolute reductions in invasive cancer (cervical and other HPV cancers, as relevant) post-vaccination	Y	Y	As appropriate to evaluation	Y

B: both sexes; CIN2+: cervical intraepithelial neoplasia grade 2 and above; F: female; male; N: no; Y: yes.